AbbVie's blockbuster hopeful Rinvoq, J&J's Spravato eye EU rollouts, thanks to new backing

abbvie
AbbVie's Rinvoq scored an early nod to treat rheumatoid arthritis patients in Europe. (AbbVie)

Painted as the follow-up drug to megablockbuster Humira, AbbVie’s JAK med Rinvoq is already notching blockbuster forecasts from market watchers. A green light to treat European patients should give the rheumatoid arthritis med a leg up in reaching that lofty goal.

Thursday, the EU’s Committee for Medicinal Products for Human Use (CHMP) gave the go-ahead to Rinvoq to treat RA patients who have failed on a prior disease-modifying therapy

The positive CHMP opinion, among seven issued by the key committee this go-round, puts the drug a step closer to new markets after its FDA nod and U.S. rollout in mid-August.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

AbbVie said in a release that it expects a full European Commission approval for Rinvoq within 67 days.

RELATED: AbbVie scores blockbuster approval for RA med Rinvoq, its crucial Humira follow-up

Rinvoq’s win wasn’t the only news from a busy day for the CHMP: Six other meds were also given a positive opinion to treat European patients, including a controversial ketamine derivative from Johnson & Johnson and an Ebola vaccine from Merck.

Spravato, J&J’s nasal ketamine-derivative spray, received a nod to treat patients with major depressive disorder (MDD) after its FDA approval back in March. The med was approved as the first new treatment for MDD in decades but only in patients who've failed two or more previous treatments.

In September, Spravato added to standard-of-care notched a trial win in reducing primary symptoms after 24 hours, compared with a combination of placebo and standard-of-care therapy. While a small subset of patients fall under that potential indication, J&J touted the new data as part of a “robust package” of results in MDD.

RELATED: Merck preps big shipment of Ebola vaccine amid deadly Congo outbreak: report

Merck’s Ebola vaccine Ervebo, already at work fighting a long-running outbreak in Central Africa, also won backing from the key EU committee.

Back in January, Merck pledged 120,000 doses to aid officials combating the virus, on top of the 100,000 doses it had previously shipped to the World Health Organization (WHO). Congo’s health ministry designated the outbreak last August.

In May, after Merck’s supplies ran short, the WHO opened the door to an experimental vaccine from J&J to fill in the gaps in treating patients.

The four other drugs winning go-aheads from CHMP Thursday were Xeris’ shelf-stable glucagon injector Baqsimi, Melinta’s Quofenix for the treatment of adult patients with acute bacterial skin and skin structure infections, a pegfilgrastim biosimilar from Mundipharma and Amgen’s bone drug Evenity, which previously had not been recommended by the committee.

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.